Interaction When the incidence of a disease in the presence of two or more risk factors differs from the incidence rate expected to result from their individual.

Slides:



Advertisements
Similar presentations
Natural History of Disease: Prevention and Prognosis Dr. Namvar Zohoori Epidemiology Research Unit Dr. Namvar Zohoori Epidemiology Research Unit.
Advertisements

Oncologic Drugs Advisory Committee
Dr K N Prasad MD., DNB Community Medicine
HIGH DOSES OF VITAMIN D TO REDUCE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMIZED TRIAL An Lehouck, PhD; Chantal Mathieu, MD, PhD;
Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Conditional Logistic Regression for Matched Data HRP /25/04 reading: Agresti chapter 9.2.
Multiple Choice Questions for discussion
Dr. Abdulaziz BinSaeed & Dr. Hayfaa A. Wahabi Department of Family & Community medicine  Case-Control Studies.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Lecture 4: Assessing Diagnostic and Screening Tests
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
Prevalence The presence (proportion) of disease or condition in a population (generally irrespective of the duration of the disease) Prevalence: Quantifies.
Lecture 6 Objective 16. Describe the elements of design of observational studies: (current) cohort studies (longitudinal studies). Discuss the advantages.
Measures of Association
Case-control study Chihaya Koriyama August 17 (Lecture 1)
S. Mazloomzadeh MD, PhD COHORT STUDIES Learning Objectives To develop an understanding of: - What is a cohort study? - What types of cohort studies are.
MBP1010 – Lecture 8: March 1, Odds Ratio/Relative Risk Logistic Regression Survival Analysis Reading: papers on OR and survival analysis (Resources)
Case Control Study Dr. Ashry Gad Mohamed MB, ChB, MPH, Dr.P.H. Prof. Of Epidemiology.
Statistics for the board September 14 th 2007 Jean-Sebastien Rachoin MD.
Acknowledgements This report differs from the submitted abstract due to further subdivision of patients into analytic and non- analytic, and focus on the.
Evaluating Screening Programs Dr. Jørn Olsen Epi 200B January 19, 2010.
Lecture 5: The Natural History of Disease: Ways to Express Prognosis
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
Compliance Original Study Design Randomised Surgical care Medical care.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
III. Measures of Morbidity: Morbid means disease. Morbidity is an important part of community health. It gives an idea about disease status in that community.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
Experiments Textbook 4.2. Observational Study vs. Experiment Observational Studies observes individuals and measures variables of interest, but does not.
Epidemiological Study Designs And Measures Of Risks (1)
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
18 Font Tex for Captions of Images/Charts/Graphs/Etc. AbstractMethods Background Implications References Results Background: Anecdotal evidence suggests.
CHP400: Community Health Program-lI Mohamed M. B. Alnoor Muna M H Diab SCREENING.
Characterstic of disease
Clinical Epidemiology
Diagnostic Test Studies
Instructional Objectives:
Study Designs Group Work
Types of Research Studies Architecture of Clinical Research
Present: Disease Past: Exposure
Lecture notes on epidemiological studies for undergraduates
Treatment allocation bias
Epidemiological Studies
CASE-CONTROL STUDIES Ass.Prof. Dr Faris Al-Lami MB,ChB MSc PhD FFPH
بسم الله الرحمن الرحيم COHORT STUDIES.
Study design.
Types of Errors Type I error is the error committed when a true null hypothesis is rejected. When performing hypothesis testing, if we set the critical.
EXPERIMENTAL STUDIES.
Migrant Studies Migrant Studies: vary environment, keep genetics constant: Evaluate incidence of disorder among ethnically-similar individuals living.
What is Screening? Basic Public Health Concepts Sheila West, Ph.D.
Ggjfتبغبغب باسمه تعالی اپیدمیولوژی بالینی مبحث: انواع مطالعات.
Lecture 1: Fundamentals of epidemiologic study design and analysis
Public Health Phase 3A Abigail Aitken
What is Screening? Basic Public Health Concepts Sheila West, Ph.D.
EXPERIMENTAL STUDIES.
Lecture 2 Cluster Investigation Dr. Bartlett and Dr. Geary Olsen
ERRORS, CONFOUNDING, and INTERACTION
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Epidemiology MPH 531 Analytic Epidemiology Case control studies
Mpundu MKC MSc Epidemiology and Biostatistics, BSc Nursing, RM, RN
The objective of this lecture is to know the role of random error (chance) in factor-outcome relation and the types of systematic errors (Bias)
How to assess an abstract
Interpreting Epidemiologic Results.
Objectives: To know the different types and varieties of designs that are commonly used in medical researches. To know the characteristics, advantages.
Cohort and longitudinal studies: statistics
RISK ASSESSMENT, Association and causation
Effect Modifiers.
Basic statistics.
EXPERIMENTAL STUDIES.
Presentation transcript:

The objective of this lecture is to have an idea about some advanced subjects in Epidemiology

Interaction When the incidence of a disease in the presence of two or more risk factors differs from the incidence rate expected to result from their individual effect. Antagonism and synergism :- Additive Multiplicative

12 I.R. with presence of factor A 20 I.R. with presence of factor B 1- Additive :- 4 = Usual I.R. of the disease without presence of factor A or B 12 I.R. with presence of factor A 20 I.R. with presence of factor B 12-4 = I.R. because of factor A alone 20-4 = I.R. because of factor B alone Interaction of factors A+B=4+8+16=28 Attribute Risk Factor B Factor A - + 4 12 4+8 20 4+8+16 4+16

2- Multiplicative :- I.R. in the presence of interaction of factor A & B = 4x3x5x= 60 Factor B Factor A - + 4 12 3x4 RR 20 3x5x4 5x4 RR

Agreement An epidemiological statistical method which shows how much two investigators agree in their results excluding chance factors

1- Percent agreement : ex 1- Percent agreement : ex. Reading x-ray results by two radiologists, the reading will be either: abnormal, suspected, doubtful or normal: Examiner I P O N M Normal L K J I Doubtful H G F E Suspected D C B A Abnormal Examiner II Percent Agreement = X 100 A+F+K+P Total readings

2- In paired observations in which at least one of the findings in each pair was positive, percent agreement = X100 Observer 1 Positive Negative Observer 2 positive a b Negative c d (ignore) a a+b+c

Kappa Statistics : by Cohen 1960 To exclude chance that two unprofessional persons brought from the street and tackle +ve or – ve. The example is CA breast staging by 2 pathologists: Grading by pathologist A Grading by pathologist B Grade II Grade III 100 60 5 65 4 31 35 64 36 Kappa = % observed agreement = X 100 = 91% Percent observed agreement – percent agreement expected by chance alone 100% - percent agreement expected by chance alone 60+31 100

So the new expected results (by chance alone)will be : Kappa : (we have to get % agreement expected by chance that is if pathologist I is working by chance, he will diagnose 60% of the specimens as grade II so if he DX. 60 % of all as stage II (even of the second pathologist) so : 60%x65 =39 60%x35 =21 So the new expected results (by chance alone)will be : 100 21 Grade III 26 Grade II pathologist B pathologist A 39 14 38 %agreement = = 53’% expected by chance alone,so Kappa = = =80% 39 +14 100 91% - 53% 100% - 53% 47

Crossover 1- planned : in randomized trials Randomized New Rx. Group 1 Current Rx. Group 2 Group 1

No surgery 2- Unplanned: Randomized Surgical surgery Refuse surgery Medical Require surgery

Compliance Non compliance Drop out Drop in How to assess Compliance : examination, calculate the # of tablets, tests, regularity of visits,…. Treatment of non- compliance : education, rewarding, sometime some sort of punishment.

Types Of Controls Hospital based : Easily identified Aware of antecedent exposure Subjected to the same intangible selection Factors of the cases But they are ill

2.Population based: No selection bias, healthy people, the result could be generalized Costly, busy people, less motivated, may not recall exposures with the same level of accuracy as the diseased person

3.Special groups: Friends, relatives, neighbors… Healthy, easy, not costly and cooperative…. Confounding factors related to ethnic background

4.Single controls: ordinary controls, individual or groups 5.Multiple Control: as in CA, leukemia and x-ray exposure 6. Individual Controls: pre and post

7. Matched Pairs: Controls Cases Exposed Not exposed A B C d

1.Case fatality rate: usually for short term, acute conditions. Expressing Prognosis 1.Case fatality rate: usually for short term, acute conditions. For chronic disease and cancer we use:

2. Five-year survival: The percent of patients who are alive 5 years after treatment begins or 5 years after diagnosis. Nothing magical about the number (5) i.e. it could be 7 or 10 and no biological changes occur during this period to justify it’s use but they see that usually most of deaths from cancer occur within this period so it is used as an index of success in cancer treatment. Two problems: - Lead time bias - 5 years of observation is necessary

Number of alive at the end of the year 3.Observed survival: Year of treatment Number of Pat. treated Number of alive at the end of the year 1st. 2nd. 3rd. 4th 5th. 2008 92 48 22 11 8 7 2009 88 42 18 10 6 2010 76 36 16 - 2011 98 50 23 2012 84 40 Total 438 176 79 32 14

P1= 176 x100 438 P2= 79 x100 176-40 P3= 32 x100 79-23 P4= 14 x100 32-11 P5= 7 x100 14-6

Probability of surviving 1year = P1 Probability of surviving 2year = P1 x P2 Probability of surviving 3year = P1 x P2 x P3 Probability of surviving 4year = P1 x P2 x P3 x P4 Probability of surviving 5year = P1 x P2 x P3 x P4 x P5

4. Median survival time : Why we use MST? The length of time that half of the study population survives. Why we use MST? Less affected by extremes than the mean If we use the mean we have to wait till all the patients die.

5. Relative survival rate: Observed survival in people with the disease Expected survival if the disease is absent